The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
Open accessAbstract
The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies were identified and 46 studies including 12 155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse in all patients (HR=1.93 (95% confidence interval (CI): 1.74-2.14); P<0.001), in node-negative patients (HR=2.31 (95% CI: 1.83-2.92); P<0.001) and in node-positive patients (HR=1.59 (95% CI: 1.35-1.87); P<0.001). Furthermore, Ki-67/MIB-1 positivity is associated with worse survival in all patients (HR=1.95 (95% CI: 1.70-2.24; P<0.001)), node-negative patients (HR=2.54 (95% CI: 1.65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“The individual HR estimates were combined into an overall HR using the Peto’s method that was first used and published in 1985 (Yusuf et al, 1985).”
MethodGene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schlüuter, C., Galle, J., & Gerdes, J. (1992) · The Journal of Pathology · doi:10.1002/path.1711680404 · Cited by 1,447
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Language bias in randomised controlled trials published in English and German
Egger, M., Zellweger-Zähner, T., Schneider, M., Junker, C., Lengeler, C., & Antes, G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02419-7 · Cited by 1,028
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
Proliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Meta-analysis of the literature or of individual patient data: is there a difference?
Stewart, L. A., & Parmar, M. K. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)93004-k · Cited by 769
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.576 · Cited by 697
Common markers of proliferation
Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650 · cited 1×
“…gene array techniques have revealed the Ki-67 gene’s role in several ‘proliferation signatures’, showing that a set of genes with increased expression patterns is correlated with tumour cell proliferation rates, as assessed by the Ki-67 labelling index (Perou et al, 1999; Whitfield et al, 2006).”
BackgroundGrégoire, G., Derderian, F., & Le Lorier, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00098-b · Cited by 526
Invited commentary: a critical look at some popular meta-analytic methods
Greenland, S. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117248 · Cited by 511
Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500
Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., & Era, S. (2005) · Oncology Reports · doi:10.3892/or.14.2.425 · Cited by 366
Estrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast Cancers
Oh, D. S., Troester, M. A., Usary, J., Hu, Z., He, X., Fan, C., Wu, J., Carey, L. A., & Perou, C. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2755 · Cited by 356
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., & Piccart, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi352 · Cited by 307
Self-citationKi67 immunostaining in primary breast cancer: pathological and clinical associations
Bouzubar, N., Walker, K., Griffiths, K., Ellis, I., Elston, C., Robertson, J., Blamey, R., & Nicholson, R. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.200 · Cited by 259
Trihia, H., Murray, S., Price, K., Gelber, R. D., Golouh, R., Goldhirsch, A., Coates, A. S., Collins, J., Castiglione‐Gertsch, M., & Gusterson, B. A. (2003) · Cancer · doi:10.1002/cncr.11188 · Cited by 189
Spyratos, F., Ferrero‐Poüs, M., Trassard, M., Hacène, K., Phillips, E., Tubiana‐Hulin, M., & Le Doussal, V. (2002) · Cancer · doi:10.1002/cncr.10458 · Cited by 186
Keshgegian, A. A., & Cnaan, A. (1995) · American Journal of Clinical Pathology · doi:10.1093/ajcp/104.1.42 · Cited by 184
Pinder, S., Wencyk, P., Sibbering, D., Bell, J., Elston, C., Nicholson, R., Robertson, J., Blamey, R., & Ellis, I. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.30 · Cited by 179
Minichromosome Maintenance Protein 2 Is a Strong Independent Prognostic Marker in Breast Cancer
Gonzalez, M. A., Pinder, S. E., Callagy, G., Vowler, S. L., Morris, L. S., Bird, K., Bell, J. A., Laskey, R. A., & Coleman, N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.121 · Cited by 158
Thor, A. D., Liu, S., Moore, D. H., & Edgerton, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.470 · Cited by 137
Esteva, F. J., Şahin, A. A., Smith, T. L., Yang, Y., Pusztai, L., Nahta, R., Buchholz, T. A., Buzdar, A. U., Hortobágyi, G. N., & Bacus, S. S. (2004) · Cancer · doi:10.1002/cncr.11940 · Cited by 135
Liu, S., Edgerton, S. M., Moore, D. H., & Thor, A. D. (2001) · PubMed · Cited by 122
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
Michalides, R. J. A. M., van Tinteren, H., Balkenende, A., Vermorken, J. B., Benraadt, J., Huldij, J. C., & van Diest, P. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600072 · Cited by 115
From Science to Practice: Meta-analyses Using Individual Patient Data Are Needed
Oxman, A. D. (1995) · JAMA · doi:10.1001/jama.1995.03530100085040 · Cited by 113
Jensen, V., Ladekarl, M. B., Holm‐Nielsen, P., Melsen, F., & Sørensen, F. B. (1995) · The Journal of Pathology · doi:10.1002/path.1711760405 · Cited by 112
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.
Brown, R. W., Allred, C., Clark, G. M., Osborne, C. K., & Hilsenbeck, S. G. (1996) · PubMed · Cited by 109
Prognostic and predictive factors revisited
Hayes, D. F. (2005) · The Breast · doi:10.1016/j.breast.2005.08.023 · Cited by 107
MIB-1 labelling index is an independent prognostic marker in primary breast cancer
Jansen, R. L. H., Hupperets, P. S. G. J., Arends, J. W., Joosten-Achjanie, S., Volovics, A., Schouten, H. C., & Hillen, H. F. P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.515 · Cited by 106
Galiègue, S., Casellas, P., Kramar, A., Tinel, N., & Simony-Lafontaine, J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0988 · Cited by 104
Kronblad, Å., Jirström, K., Rydén, L., Nordenskjöld, B. A., & Landberg, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21676 · Cited by 101
Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step
Piedbois, P., & Buyse, M. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.924 · Cited by 94
Pellikainen, M. J., Pekola, T. T., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., & Kosma, V.-M. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.56.3.214 · Cited by 93
Pestalozzi, B. C., Luporsi, É., Jost, L. M., & Bergh, J. C. S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi825 · Cited by 92
Seshadri, R., Leong, A. S. ‐., McCaul, K. A., Firgaira, F. A., Setlur, V., & Horsfall, D. J. (1996) · International Journal of Cancer · Cited by 90
Clahsen, P. C., de Velde, C. J. H. V., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroïde, A., van den Broek, L., & van de Vijver, M. J. (1999) · European Journal of Surgical Oncology · doi:10.1053/ejso.1999.0657 · Cited by 90
Kröger, N. M., Milde‐Langosch, K., Riethdorf, S., Schmoor, C., Schumacher, M. C., Zander, A. R., & Löning, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1340 · Cited by 90
Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer
Rudolph, P., Alm, P., Heidebrecht, H. J., Bolte, H., Ratjen, V., Baldetorp, B., Fernö, M., Olsson, H. L., & Parwaresch, R. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.271 · Cited by 73
Haerslev, T., Jacobsen, G. K., & Zedeler, K. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806492 · Cited by 70
Domagała, W., Markiewski, M. M., Harezga, B., Dukowicz, A., & Osborn, M. (1996) · PubMed · Cited by 68
Gaglia, P., Bernardi, A., Venesio, T., Caldarola, B., Lauro, D., Cappa, A. P. M., Calderini, P., & Liscia, D. S. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90284-m · Cited by 66
Weikel, W., Beck, T., Mitze, M., & Knapstein, P. G. (1991) · Breast Cancer Research and Treatment · doi:10.1007/bf01990030 · Cited by 55
The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67
Goodson, W. H., Moore, D. H., Ljung, B., Chew, K., Mayall, B. H., Smith, H. S., & Waldman, F. M. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006344010050 · Cited by 47
Standards for Reporting Prognostic Tumor Marker Studies
Alonzo, T. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3778 · Cited by 47
Perera, S. M., Thomas, J. A., Burke, M. M., & Crawford, D. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199802)184:2<130::aid-path19>3.0.co;2-w · Cited by 45
BECK, T. M., Weller, E. E., Weikel, W., Brumm, C., Wilkens, C., & Knapstein, P. G. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.1104 · Cited by 45
Bukholm, I., Bukholm, G., Holm, R., et al. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.56.5.368 · Cited by 39
Gasparini, G., Boracchi, P., Bevilacqua, P., Mezzetti, M., Pozza, F., & Weidner, N. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666182 · Cited by 30
Weikel, W., Brumm, C., Wilkens, C., Beck, T., & Knapstein, P. G. (1995) · PubMed · Cited by 20
Bevilacqua, P., Verderio, P., Barbareschi, M., Bonoldi, E., Boracchi, P., Palma, P. D., & Gasparini, G. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806494 · Cited by 19
Cited by
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationSystematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
Self-citation
Metadata
- Authors
- de Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M.
- Venue
- British Journal of Cancer
- Published
- 2007-04-24
- Volume
- 96
- Issue
- 10
- Pages
- 1504-1513
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2001968322
- Cited by
- 959
- References
- 61
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.